Suite of Smart Heart Failure Devices Offers More-Effective Pacing, Expanded MRI Access
DUBLIN - Feb. 24, 2017 - Medtronic plc (NYSE:MDT) today announced that it has received CE (Conformité Européenne) Mark for a suite of quadripolar cardiac resynchronization therapy pacemakers (CRT-Ps) that also allow patients to receive MRI (magnetic resonance imaging) scans in either 1.5 or 3 Tesla (T) machines. This complete line of CRT-Ps, available in Europe in March, includes the Percepta(TM) Quad CRT-P MRI SureScan(TM), Serena(TM) Quad CRT-P MRI SureScan(TM) and Solara(TM) Quad CRT-P MRI SureScan(TM), and enables proactive heart failure management alongside industry-leading pacing technology and patient access to the most advanced diagnostic imaging procedures available. These devices are not yet approved for sale in the United States.
"Quadripolar devices, such as these new pacemakers, allow more pacing programming options, which allows us to better optimize CRT delivery," said Dr. Massimo Mantica of Istituto Clinica Sant'Ambrogio, Milano, Italy. "Advanced technology continues to give us smarter devices that enable more personalized treatment for patients."